Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats by tamoxifen and melatonin: Metabolic alterations

Biologia

Volumn 56, Issue 5, 2001, Pages 565-571

  Chamilová, Martina ^a   Bojková, Bianka ^a   Kubatka, Peter ^a   Kalická, Katarína ^a   Adámeková, Eva ^a   Ahlers, Ivan ^a   Ahlersová, Eva ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Mammary carcinogenesis; Melatonin; Metabolic changes; Rats; Tamoxifen

Indexed keywords

ANIMALIA;

EID: 17944379914     PISSN: 00063088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ARAKI, E. & YAMAMOTO, H. 1992. Serum HDLcholesterol in patients with breast carcinoma. Rinscho Byori 40: 326-328.
2. BARTLETT, G. R. 1959. Phosphorus assay in column chromatography. J. Biol. Chem. 234: 466-468.
3. BASU, T. K. &LIAMS, D. C. 1975. Plasma and body lipids in patients with carcinoma of the breast. Oncology 31: 172.
4. BLASK, D. E, HILL, S. M., & PELLETIER, D. B. 1988. Oncostatic signaling by the pineal gland and melatonin in the control of breast cancer, pp. 195206. In: GUPTA, D., ATTANASIO, A. & REITER, R. J. (eds) The Pineal Gland and Cancer, Brain Research Promotion, London - Tübingen. &
5. Cos, S. & SÁCHEZ-BARCELÓ, E. 2000. Melatonin and mammary pathological growth. Front. Neuroendocrinol. 21: 133-170.
6. DESSI, S., BATETTA, B., Pui.isci, D., SPANO, O., CHERCHI, R., LANFRANCO, G., TESSITURE, L., CosTELLi, P., BACCINO, F. M. & PANI, P. 1992. Altered pattern of lipid metabolism in patients with lung cancer. Oncology 49: 436-441.
7. DNISTRIAN, M. A., SCHWARTZ, K. M., SMITH, A. C. & SCHWARTZ, C. D. 1993: Effect of tamoxifen on serum cholesterol and Hpoproteins during chemohormonal therapy. Clin. Chim. Acta 223: 43-52.
8. DOUGLAS, R. G. & SHAW, J. H. F. 1990. Metabolic effects of cancer. Brit. J. Surg. 77: 246-256.
9. FEINLEIB, M. 1983. Rewiev of the epidemiological evidence for a possible relationship between hypocholesterolemia and cancer. Cancer Res. 43: 2503.
10. FISHER, B., CONSTANTINO, J. P., REDMOND, C. K., FISHER. E. R., WICKERHAM, D. L., CROWN, W. M. & NSABP CONTRIBUTORS. 1994. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86: 527-537.
11. GARCIA, J. J., REITER, R. J., ORTIZ, G. C., OH, C. S., TANG, L., Yu, B. P. & ESCAMES, G. 1998. Melatonin enhances tamoxifen ability to prevent the reduction in microsomal membrane fluidity induced by lipid peroxidation. J. Membrane Biol. 162: 59-62.
12. GUARDIOLA-LEMAITRE, B. 1997. Toxicology of melatonin. J. Biol. Rhythms 6: 697-706.
13. JORDAN, V. C. 1976. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer 12: 419424.
14. KOTHARI, A., BORGES, A., INGLE, A. & KOTHARI, L. 1997. Combination of melatonin and tamoxifen as a chemoprophylaxis against N-nitroso-Nmethylurea-induced rat mammary tumors. Cancer Lett. Ill: 59-66.
15. KöKöGLU, E., KARAARSLAN, I., KARAARSLAN, H. M. & BALOGLU, H. 1994. Alterations of serum lipids and Hpoproteins in breast cancer. Cancer Lett. 82: 175-178.
16. KRISTENSEN, B., EJLERTSEN, B., DALGAARD, P., LARSEN, L., HOLMEGAARD, S. N. & et al. 1994. Tamoxifen and bone metabolism in postmenopausal low risk breat cancer patients: a randomized study. J. Clin. Oncol. 12: 992-997.
17. KUBATKA, P., BOJKOVÁ, B., KALICKÁ, K., CHAMILOVÁ, M., ADÁMEKOVÁ, E., AHLERS, L, AHLERSOVÁ, E. & ČERMÁKOVÁ, M. 2001. Effect of tamoxifen and melatonin on mammary gland cancer induced by N-methyl-N-nitrosourea respectively by 7,12-dimethylbenz/a/anthracene in female Sprague-Dawley rats. Folia Biol., Praha 47: 5-10.
18. MCDONALD, C. C. & STEWART, H. J. 1991. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Brit. Med. J. 303: 435-437.
19. MNÍCHOVÁ, M., MÔCIKOVÁ, K., KUBATKA, P., AHLERSOVÁ, E. & AHLERS, I. 1999. Metabolic changes in N-methyl-N-nitrosourea induced mamary carcinogenesis in Sprague-Dawley female rats. Physiol. Res. 48: 14P.
20. ROE, J. H. & DAILEY, R. 1966. The determination of glycogen with anthrone reagent. Analyt. Biochem. 15: 245-250.
21. ROSE, G., BLACKBURN, H., KEYS, A., TAYLOR, H. L., KANNEL, W. B., PAUL, O., REID, D. D. & STAMLER, J. 1974. Colon cancer and blood cholesterol. Lancet 1: 181.
22. RUGGIERI, S., MUGNAI, G., MANNINI, A., CALORINI, L., FALLANI, A., BARLETTA, E., MANNORI, G. & CECCONI, O. 1999. Lipid characteristics in metastatic cells. Clin. Exp. Metast. 17: 271-276.
23. RUTQVIST, L. E., JOHANSSON, H., SlGNOMKLAO, T., JOHANSSON, U., FORNANDER, T. & WlLKING, A. 1995. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl. Cancer Inst. 87: 645-651.
24. SATCH, K. 1978. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin. Chim. Acta 90: 37-43.
25. SHIMA, T., CHUN. S.-J., NIIJIMA, A., BIZOT-ESPIARD J.-G., GUARDIOLA-LEMAITRE. B., HOSOKAWA, M. & NAGAI, K. 1997. Melatonin suppresses hyperglycemia caused by intracerebroventricular in-jection of 2-deoxy-D-glucose in rats. Neurosci. Lett. 226: 119-122.
26. SPIEGEL, R. J.. SCHAEFER. E. J., MCGRATH, L. T. & EDWARDS, B. K. 1982. Plasma lipid alterations in leukemia and lymphoma. Arn. J. Med. 72: 775.
27. TAN, D. X., CHEN, L. D., POEGGELER, B.. MANCHESTER, L. C. & REER. R. J. 1993. Melatonin, a potent endogenous hydroxyl radical scavenger. Endocrin. J. 15: 57-60.
28. VAUGHAN, M. K. & VAUGHAN, G. M. 1993. Metabolic and thyroidal consequences of melatonin administration in mammals, pp. 311-347. In: Yu, H. S. & REITER, R. J. (eds) Melatonin - Biosynthesis, Physiological Effects, and Clinical Implications, CRC Press, Boca Raton.
29. WILSON, S. T., BLASK, D. E. & LEMUS-WILSON, A. M. 1992. Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J. Clin. Endocrinol. Metab. 75: 669-670.
30. ZLATKIS, A., ZAK, B. &t BOYLE, A. J. 1953. A new method for the direct determination of cholesterol. J. Lab. Clin. Med. 41: 486-490.